| Literature DB >> 29713080 |
Taka-Aki Koshimizu1, Kenji Honda2, Sachi Nagaoka-Uozumi2, Atsuhiko Ichimura3,4, Ikuo Kimura5, Michio Nakaya6, Nobuya Sakai7, Katsushi Shibata7, Kentarou Ushijima8, Akio Fujimura8, Akira Hirasawa9,10, Hitoshi Kurose6, Gozoh Tsujimoto9, Akito Tanoue11, Yukio Takano12.
Abstract
Chronic morphine exposure upregulates adenylate cyclase signaling and reduces analgesic efficacy, a condition known as opioid tolerance. Nonopioid neurotransmitters can enhance morphine tolerance, but the mechanism for this is poorly understood. We show that morphine tolerance was delayed in mice lacking vasopressin 1b receptors (V1bRs) or after administration of V1bR antagonist into the rostral ventromedial medulla, where transcripts for V1bRs and μ-opioid receptors are co-localized. Vasopressin increased morphine-binding affinity in cells expressing both V1bR and μ-opioid receptors. Complex formation among V1bR, β-arrestin-2, and μ-opioid receptor resulted in vasopressin-mediated upregulation of ERK phosphorylation and adenylate cyclase sensitization. A leucine-rich segment in the V1bR C-terminus was necessary for the association with β-arrestin-2. Deletion of this leucine-rich segment increased morphine analgesia and reduced vasopressin-mediated adenylate cyclase sensitization. These findings indicate that inhibition of μ-opioid-receptor-associated V1bR provides an approach for enhancing morphine analgesia without increasing analgesic tolerance.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29713080 DOI: 10.1038/s41593-018-0144-y
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 24.884